abbexa

Human SARS-CoV-2 Neutralizing Antibody ELISA Kit | abx365086

(No reviews yet) Write a Review

SKU:: abx365086
UPC:
MPN:
Availability:: Usually shipped in 5 working days
Size:: 96 Tests

€661.00

Current Stock:

Quantity:

Frequently bought together:

Description

Description

Human SARS-CoV-2 Neutralizing Antibody ELISA Kit. Cat# abx365086. Supplier: abbexa.

Human Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody ELISA Kit is an ELISA kit for semi-quantitative detection of SARS-CoV-2/COVID-19 Neutralizing Antibodies in Human serum and plasma.

Target	SARS-CoV-2 Neutralizing Antibody
Reactivity	Human
Tested Applications	ELISA
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Storage	Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.
Validity	The validity for this kit is 6 months.
Stability	The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5% within the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same user throughout.
Test Range	15.6 ng/ml - 500 ng/ml
Sensitivity	9.38 ng/ml
Detection Method	Colorimetric
Assay Type	Indirect
Sample Type	Serum, plasma and other biological fluids.
Availability	Shipped within 5-12 working days.
Note	This product is for research use only. The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.